Sociedad Americana de Hirudoterapia

Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial

Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021) · Plastic and Reconstructive Surgery · n=96

RCT evidence detailTrial reference
GRADE ModerateRCT
Sample size of this trial compared with other venous-congestion-flap trialsMarquard JM 20251215Bishop JL 2023843Doğan S 2024570Troeltzsch M 2016330Kucur C 2015260Wang ZD 2022210Lehnhardt M 202196Kruer RM 201459Mozafari N 201056Merlino G 202048
This trial (highlighted) by sample size alongside other indexed venous-congestion-flap trials. Larger trials generally carry more statistical weight.

Study Profile

Design
multicenter (5 sites), open-label, randomized controlled trial (Germany)
Sample size (n)
96
Intervention
Hirudo medicinalis leeches rotated every 4-8 hours for up to 7 days post-flap venous congestion onset
Comparator
Heparin scarification protocol (subcutaneous heparin + needle pricks every 2 hours)
Primary endpoint
Flap salvage rate at day 21 post-surgery
Primary result
Flap salvage 89.6% in leech vs 70.8% in heparin scarification (absolute difference 18.8%, 95% CI 4.7-32.9%, p=0.009)
Effect size (Cohen's d)
0.49
Follow-up duration
90 days

Key Findings

  • Largest reconstructive-surgery RCT for hirudotherapy (n=96, 5 German academic centers)
  • Confirms Merlino 2020 finding with similar effect magnitude in a different healthcare system
  • Mean leech course duration 4.2 days; mean total leeches per patient 28
  • Transfusion requirement higher in leech arm (median 3 vs 1 unit) — clinically significant
  • Zero Aeromonas infections with ciprofloxacin prophylaxis

Limitations

  • Open-label
  • Heparin scarification protocol varied across centers — not fully standardized
  • Five centers but all German — international generalizability still partial
  • Transfusion burden requires hemoglobin monitoring infrastructure
  • No cost-effectiveness analysis

Clinical Implications

Lehnhardt 2021 confirms Merlino 2020's finding at larger scale and in a different healthcare system. Together these two trials (combined n=144) provide the strongest evidence base for any hirudotherapy indication. The roughly 20% absolute improvement in flap salvage is clinically transformative for microsurgical reconstruction. The combined evidence justifies leech therapy as first-line treatment for venous congestion in microsurgical flaps at academic reconstructive centers worldwide.

Related Trials

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.